ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

INTEGRILIN
Thromboembolic disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

INTEGRILIN Rx

Generic Name and Formulations:
Eptifibatide 0.75mg/mL, 2mg/mL; soln for IV inj.

Company:
Merck & Co., Inc.

Therapeutic Use:

Indications for INTEGRILIN:

For acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI), including those undergoing intracoronary stenting.

Adult:

See literature. Use in combination with aspirin and heparin. ACS: 180micrograms/kg IV bolus, followed by a continuous IV infusion of 2micrograms/kg/min until discharge or CABG surgery, up to 72hrs. If PCI planned, continue infusion until discharge, or for up to 18–24hrs after procedure, whichever comes first, allowing up to 96hrs of therapy. PCI: 180micrograms/kg IV bolus followed by 2micrograms/kg/min infusion; repeat 180micrograms/kg IV bolus 10mins after the 1st bolus; continue infusion until discharge, or for up to 18–24hrs, whichever comes first, minimum 12hr-infusion recommended. CrCl <50mL/min: reduce infusion rate to 1microgram/kg/min.

Children:

Not recommended.

Contraindications:

Bleeding diathesis or active abnormal bleeding within previous 30 days. Severe uncontrolled hypertension. Major surgery within previous 6 weeks. History of stroke within 30 days or any history of hemorrhagic stroke. Concomitant parenteral GP IIb/IIIa inhibitors. Renal dialysis.

Warnings/Precautions:

See literature. Discontinue if uncontrolled bleeding occurs. Platelet count <100,000/mm3. Properly care for femoral artery access site to minimize bleeding. Minimize other arterial and venous punctures, IM inj, catheter use, intubation, NG tubes, to lower bleeding risk; avoid use of non-compressible IV access sites. Do baseline platelet counts, hemoglobin, hematocrit, others and monitor during therapy (see literature). Discontinue if confirmed thrombocytopenia occurs. Renal insufficiency. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

Antiplatelet effects may be potentiated by thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole.

Pharmacological Class:

Antiplatelet.

Adverse Reactions:

Bleeding, intracranial hemorrhage, stroke, thrombocytopenia, hypersensitivity reactions, hypotension.

Generic Availability:

YES

How Supplied:

Vial 0.75mg/mL (100mL)—1; 2mg/mL (10mL, 100mL)—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs